LifeNet Health to launch CardioGRAFT decell pulmonary patch with MATRACELL technology

LifeNet Health, a leading allograft bio-implant company, will nationally launch the CardioGRAFT® decell pulmonary patch with MATRACELL™ technology at the Society of Thoracic Surgeons annual meeting in Ft. Lauderdale, Fla., on January 24.

MATRACELL™ is one of several new and advanced technology platforms that LifeNet Health has developed to enhance the utility and clinical effectiveness of human allograft tissue.  MATRACELL™ technology is a patented and validated process to render allograft tissue acellular, removing over 99% of the donor genetic material while retaining the native biomechanical strength of the tissue.

The CardioGRAFT® decell pulmonary patch with MATRACELL™ technology is currently being implanted in four clinical centers that specialize in correcting life threatening pediatric congenital heart conditions. The sites will be generating data regarding clinical results for publication and presentation.

Surgeons will be able to discuss clinical experience and the science behind MATRACELL™  Technology at the Society of Thoracic Surgeons annual meeting with Richard Hopkins, MD, Director, Cardiac Surgery Research Laboratories Chief, Adolescent/Adult Congenital Cardiac Surgery Professor of Surgery, UMKC at Children's Mercy Hospitals and Clinics Kansas City, MO, and Alyce Linthurst Jones, Ph.D., LifeNet Health Research and Development Project Manager in Virginia Beach, VA.

"We are excited to offer MATRACELL™ to surgeons across the country to help restore health to pediatric heart patients. MATRACELL™ has the potential to improve clinical outcomes and increase implant durability. We hope this will reduce the number of surgeries any child will have to undergo with this improved technology," said Rony Thomas, LifeNet Health CEO and President.